Alirocumab (Praluent) Dosing in Renal Impairment: What the Evidence Shows
Evidence-based guide to alirocumab (Praluent) dosing in patients with renal impairment, including CKD stages 3-5, dialysis, and nephrotic syndrome. Covers pharmacokinetics, trial data, and clinical recommendations.
Read clinical review